CU Gynecologic Oncology Research

Join us for the Pharmacology Seminar Series as Dr. Elizabeth Woodruff discusses how chronic stress influences #HGSC progression and immune response through adrenergic signaling in the omentum. #OvarianCancer #GynOnc #CUAnschutz

Date 📅: Mon, 10/20/25, 12:00 PM MST
Location📍: RC1 North, Room 6107

Dr. Walsh with 9News

✨Dr. Christine Walsh, a leading Gynecologic Oncologist at the University of Colorado Anschutz, recently appeared on 9News to discuss genetics' role in gyn cancers as well as share insights on ovarian cancer.

👉 Watch the full interviews here: bit.ly/3KNj0lv 

#CancerGenetics #GynOc #CUAnschutz

‘I Love What I Do’: While She Helps Patients, a Nurse Grapples with Her Own Ovarian Cancer Toni Moses, RN, says she’s grateful to be enrolled in a clinical trial led by Bradley Corr, MD, of the CU Cancer Center.

Toni Moses, RN, is battling stage IV ovarian cancer while helping others—and participating in a trial led by Dr. Brad Corr & the CU Ovarian Cancer Innovations Group. 💙 Read her powerful story: news.cuanschutz.edu/cancer-cente...

#OvarianCancer #GynOnc #CUAnschutz

Thank you to all who attended the CU Ovarian Cancer Innovations Group (OCIG) Reception during the AACR Special Conference on #OvarianCancer! 💫 It was inspiring to connect with so many passionate researchers in Denver. Let’s keep the momentum going! #AACR #CUAnschutz
@uccc-gorg.bsky.social

Congrats to Dr. Liz Woodruff (Division of Repro Science) on receiving a $10K Cancer Innovation Pilot Grant from
@cucancercenter.bsky.social!
Her study explores how social stress/isolation impacts high-grade serous carcinoma (HGSC) progression & immune response🎉 @liz-woodruff.bsky.social #CUAnschutz

🎗️Attending the AACR Conference on Ovarian Cancer?

Visit Alan Elder’s poster "Discerning mechanisms of SEMA7A in therapy resistance & tumor progression in HGSC"

Also join the CU Ovarian Cancer Innovations Group (OCIG) Reception on Saturday, Sept 20th. Register here: bit.ly/47KvpA3

#AACRovca25

🎉Dr. Kian Behbakht from CU's Ovarian Cancer Innovations Group (OCIG) was featured on #BBC The Happy Pod🎙️He discussed the development of an ovarian cancer early detection test, which is being developed in partnership with AOA Dx. #OvarianCancer #CUAnschutz

👉 Listen here: www.bbc.com/audio/play/p...

Drs. Ben Bitler & Kian Behbakht, AOA Dx (a women-owned Denver biotech), and other GynOnc researchers co-published a study on a scalable, sensitive test using lipidomic and protein biomarkers with machine learning to improve early ovarian cancer detection. View Here: www.mdpi.com/2075-4418/15...

Help us welcome Drs. Katharine Linder and Daisy Cruz, our new CU GynOnc fellows joining the University of Colorado GynOnc Research Group (GORG) Lab this Fall 2025! Excited for the expertise and passion they'll bring to advancing women’s cancer research 🎉🎉 #GynOnc #CUAnschutz #OvarianCancer

🎉Dr. Lindsay Brubaker is tackling therapy resistance in #HGSC with cutting-edge research on antibody-drug conjugates (ADCs). Backed by a competitive DOD grant, her study explores epigenetic drivers to expand and improve treatment options. View Article bit.ly/4fxHr1E #OvarianCancer #CUAnschutz

Congrats to Drs. Ben Bitler and Jim Lambert on receiving an award from Golfers Against Cancer to advance ovarian cancer immunogenic cell death (ICD) research — pushing boundaries in cancer research #OvarianCancer #GynOnc #CUAnschutz 👏👏 @uccc-gorg.bsky.social

Congrats to Scott Lin, MD, PhD Candidate, on receiving the Cancer Biology T32 award from the National Cancer Institute! This prestigious award supports 5 predoctoral students each year with funding through the University of Colorado Cancer Center. 🎉🎉 #CUAnschutz #GynOnc @uccc-gorg.bsky.social

🔬Don’t miss Session 2 of our gynecologic cancer virtual series! Scott Lin, MD, PhD Candidate, will share insights on PARP inhibitors & ovarian cancer treatment. #OvarianCancer @uccc-gorg.bsky.social

📅 Aug 11 |🕛 12–1PM MST |💻 Virtual
Topic: PARP Inhibitors
Register today! bit.ly/40k8dUE

Congrats to Team Bitler—Drs. Bitler, Corr, Sikora, Clauset, and many others—2025 CU ASPIRE Awardees🎉Their SPORE effort to advance ovarian cancer care with novel therapies & population science. #OvarianCancer #CUAnschutz @uccc-gorg.bsky.social‬ @mjsikora.bsky.social View details here: Bit.ly/4mWBRsO

Congratulations to Courtney Bailey, PhD student in Biomedical Engineering at CU Boulder and part of the Gynecologic Oncology Research Group at CU Anschutz! She was awarded the Achievement Reward for College Scientist Scholarship. Well deserved! 👏 #CUAnschutz #CUBoulder #BiomedicalEngineering #GynOnc

Dr. Kian Behbakht and AOA Dx CEO Oriana Papin-Zoghbi spoke with 360Dx about the urgent need for better ovarian cancer diagnostics, highlighting how vague symptoms delay care and the role of innovation and data in closing this critical diagnostic gap. #OvarianCancer

👏Full article: bit.ly/3ZMxqa3

The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective

Insights on IHC testing for clinical decision making - put together by our talented Gyn Onc Path team! Shout to Dr. Rebecca Wolsky.

@cucancercenter.bsky.social

www.sciencedirect.com/science/arti...

Join Computational Bioscience (CPBS) Program student Weishan Li for a talk on "Deriving Cell Type Specific Expression Profiles from HGSC using BuDDI"

Date 📅: Tomorrow (5/21/2025) 1PM MST
Location📍: RC1 North, Room 8108 & Zoom: ucdenver.zoom.us/j/9780564841...

#OvarianCancer #GynOnc #CUAnschutz

Join Human Medical Genetics and Genomics Program (HMGGP) student Samantha Lopez Alvarez for a talk on "Evaluating Expression Based HRD Predictors in Black and White HGSC Patients"

When 📅: Today (5/15/2025) 1PM – 2:30PM MST
When📍: #CUAnschutz Hensel Phelps West Auditorium
#OvarianCancer

AOA Dx Reports High Accuracy for AI-Powered Ovarian Cancer Blood Test in 1,000 Patient Study | Femtech Insider AOA Dx, a company developing blood-based diagnostics for early cancer detection, has demonstrated high accuracy in detecting ovarian cancer in symptomatic women using its AI-powered multi-omic platfor...

At the 2025 #AACR Annual Meeting, AOA Dx shared new data showing >90% AUC in early #ovariancancer detection—outperforming CA125. This finding was made in collaboration with the #CU Ovarian Cancer Innovations Group & U. of Manchester. A big step for AI in women's health. Press Release: bit.ly/433cCft

Today is World Ovarian Cancer Day #WOCD! In recognition of this important day, the CU Division of GynOnc will once again sponsor and participate in Jodi’s Race for Awareness 5k to support gyn cancers, including ovarian cancer, on 6/14/2025 in Denver. To register, please visit www.JodisRace.org

High-Grade Serous Carcinoma of the ovary, fallopian tube or peritoneum has the worst prognosis due to late diagnosis and therapy resistance. Dr. Alan Elder from the CU #GynOnc Lab aims to uncover the role of SEMA7A in therapy resistance and immunoevasion in ovarian cancer! @uccc-gorg.bsky.social

🔬Curious about gynecologic cancer research but not a science expert? Join CU DRS & CGCA’s new virtual, quarterly series making cutting-edge research easy to understand @uccc-gorg.bsky.social

📅 May 12 |🕛 12–1PM MST |💻 Virtual
Topic: Ovarian cancer early detection
Register today! loom.ly/7owjJ-g

The CU Medical Scientist Training Program (MSTP) Annual Retreat was held on 4/18/2025. Scott Lin presented his research findings on targeting the epigenetic environment of therapy-resistant ovarian cancer, and Raquel Ortega presented her exciting research on Alt-EJ and PARP inhibitors. #CUAnschutz

High-grade serous carcinoma is a tough ovarian cancer to treat and often recurs after chemotherapy. Dr. Marjon recently resubmitted a paper showing that targeting certain tumor immune cells could help make treatments like chemotherapy more effective. Wishing her luck🤞 #HGSC #CUAnschutz #GynOnc

Feasibility of assessing symptoms associated with ovarian cancer using an electronic medical intake questionnaire Symptoms occur in up to 75% of patients with early-stage ovarian cancer; as such, using a symptom inventory (SI) to stratify which patients should rec…

Early detection for ovarian cancer. Drs. Helm and Behbakht published a study on symptom screening feasibility. www.sciencedirect.com/science/arti... @cucancercenter.bsky.social @cugynonc.bsky.social @powelldrescher.bsky.social @targetovarian.bsky.social

Last month, Taylor Benson, PhD, showcased her work on identifying early biomarkers for ovarian clear cell carcinoma (OCCC) at STEM Poster Day, hosted by @projbridgeco.bsky.social!
#CancerResearch #CUAnschutz

Check out her poster: www.cuanschutz.edu/docs/librari...

Women-founded company partners with CU Anschutz to develop ovarian cancer test Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the cutting edge to detect and prevent ovarian cancer.

Yesterday, CBS interviewed Dr. Kian Behbakht and AOA Dx, a Denver-based biotech startup, about their partnership to develop a unique ovarian cancer detection test in collaboration with the CU GynOnc Research Lab at CU Anschutz #CUAnschutz #OvarianCancer #GynOnc www.cbsnews.com/colorado/vid...

Women-founded company partners with CU Anschutz to develop, test first-of-its-kind ovarian cancer detection test Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the cutting edge to detect and prevent ovarian cancer.

Early detection of ovarian cancer! www.cbsnews.com/colorado/new... @cugynonc.bsky.social @ocacademy.bsky.social

Momie Yamamoto and Ritz Iwanaga from Dr. Bitler's lab at CU Anschutz recently submitted a paper showing that Chromobox2 (CBX2) plays a role in driving HGSC progression. This suggests a potential new treatment option for HGSC patients. Wish them luck publishing their paper #HGSC #GynOnc #CUAnschutz